Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Urology and Nephrology
Published in: International Urology and Nephrology 1/2015

01-01-2015 | Nephrology - Original Paper

The association between lipid metabolism gene polymorphisms and nephropathy in type 2 diabetes: a meta-analysis

Authors: Tingting Li, Yun Shi, Jieyun Yin, Qin Qin, Sheng Wei, Shaofa Nie, Li Liu

Published in: International Urology and Nephrology | Issue 1/2015

Login to get access

Abstract

Purpose

Hyperlipidaemia has been identified as a risk factor for diabetic nephropathy via exacerbation of glomerular injury through the activation of multiple signaling pathways. This study’s aim is to assess the associations between polymorphisms of genes involved in lipid metabolism, such as apolipoprotein E (ApoE), peroxisome proliferator-activated receptor γ (PPARγ), acetyl-CoA carboxylase β (ACACB), and type 2 diabetic nephropathy (T2DN).

Methods

A search of the MEDLINE and Web of Science databases was used to identify relevant studies, and allele or genotype frequencies were pooled using fixed- or random-effects models.

Results

Forty-five studies were included in this meta-analysis, consisting of 10,920 type 2 diabetic patients with nephropathy and 16,203 type 2 diabetic patients without nephropathy. The OR for ApoE ε2 versus ε3 was 1.49 (95 % CI 1.13–1.95) in T2DN. The progression of T2DN was related to the presence of the ε2 allele and ε2 carrier with ORs of 1.72 (95 % CI 1.10–2.69) and 1.78 (95 % CI 1.18–2.69), respectively. The rs1801282 C>G variant in PPARγ presented a significant association with decreased T2DN risk, both in the G allele and GC/GG genotype with ORs of 0.77 (95 % CI 0.68–0.87) and 0.79 (95 % CI 0.69–0.92), respectively. The T allele in rs2268388 within ACACB showed an increased risk for T2DN, exhibiting an OR of 1.35 (95 % CI 1.12–1.63).

Conclusions

Our meta-analysis supports that the ApoE ε2 allele and ACACB rs2268388 C>T might act as promotion factors of nephropathy in type 2 diabetes, whereas PPARγ rs1801282 C>G is a promising candidate genetic variation for reducing susceptibility to T2DN.
Appendix
Available only for authorised users
Literature
1.
Macisaac RJ, Ekinci EI, Jerums G (2014) Markers of and risk factors for the development and progression of diabetic kidney disease. Am J Kidney Dis 63(2 Suppl 2):S39–S62PubMedCrossRef
2.
Ng MC, Baum L, So WY, Lam VK, Wang Y, Poon E, Tomlinson B, Cheng S, Lindpaintner K, Chan JC (2006) Association of lipoprotein lipase S447X, apolipoprotein E exon 4, and apoC3-455T>C polymorphisms on the susceptibility to diabetic nephropathy. Clin Genet 70(1):20–28PubMedCrossRef
3.
Shah VN, Cheema BS, Sharma R, Khullar M, Kohli HS, Ahluwalia TS, Mohan V, Bhansali A (2013) ACACbeta gene (rs2268388) and AGTR1 gene (rs5186) polymorphism and the risk of nephropathy in Asian Indian patients with type 2 diabetes. Mol Cell Biochem 372(1–2):191–198PubMedCrossRef
4.
Wu LS, Hsieh CH, Pei D, Hung YJ, Kuo SW, Lin E (2009) Association and interaction analyses of genetic variants in ADIPOQ, ENPP1, GHSR, PPARgamma and TCF7L2 genes for diabetic nephropathy in a Taiwanese population with type 2 diabetes. Nephrol Dial Transplant 24(11):3360–3366PubMedCrossRef
5.
Ganan A, Corella D, Guillen M, Ordovas JM, Pocovi M (2004) Frequencies of apolipoprotein A4 gene polymorphisms and association with serum lipid concentrations in two healthy Spanish populations. Hum Biol 76(2):253–266PubMedCrossRef
6.
Ha SK, Park HS, Kim KW, Kim SJ, Kim DH, Kim JH, Lee HY, Han DS (1999) Association between apolipoprotein E polymorphism and macroalbuminuria in patients with non-insulin dependent diabetes mellitus. Nephrol Dial Transplant 14(9):2144–2149PubMedCrossRef
7.
Hsu CC, Kao WH, Coresh J, Pankow JS, Marsh-Manzi J, Boerwinkle E, Bray MS (2005) Apolipoprotein E and progression of chronic kidney disease. JAMA 293(23):2892–2899PubMedCrossRef
8.
Liu L, Xiang K, Zheng T, Zhang R, Li M, Li J (2003) Co-inheritance of specific genotypes of HSPG and ApoE gene increases risk of type 2 diabetic nephropathy. Mol Cell Biochem 254(1–2):353–358PubMedCrossRef
9.
Guan J, Zhao HL, Baum L, Sui Y, He L, Wong H, Lai FM, Tong PC, Chan JC (2009) Apolipoprotein E polymorphism and expression in type 2 diabetic patients with nephropathy: clinicopathological correlation. Nephrol Dial Transplant 24(6):1889–1895PubMedCrossRef
10.
Kwon MK, Rhee SY, Chon S, Oh S, Woo JT, Kim SW, Kim JW, Kim YS, Jeong KH, Lee SH, Lee TW, Ihm CG (2007) Association between apolipoprotein E genetic polymorphism and the development of diabetic nephropathy in type 2 diabetic patients. Diabetes Res Clin Pract 77(Suppl 1):S228–S232PubMedCrossRef
11.
Leiva E, Mujica V, Elematore I, Orrego R, Diaz G, Prieto M, Arredondo M (2007) Relationship between Apolipoprotein E polymorphism and nephropathy in type-2 diabetic patients. Diabetes Res Clin Pract 78(2):196–201PubMedCrossRef
12.
Erdogan M, Eroglu Z, Biray C, Karadeniz M, Cetinkalp S, Kosova B, Gunduz C, Topcuoglu N, Ozgen G, Yilmaz C (2009) The relationship of the apolipoprotein E gene polymorphism Turkish Type 2 diabetic patients with and without nephropathy. J Endocrinol Invest 32(3):219–222PubMedCrossRef
13.
Ma SW, Benzie IF, Yeung VT (2008) Type 2 diabetes mellitus and its renal complications in relation to apolipoprotein E gene polymorphism. Transl Res 152(3):134–142PubMedCrossRef
14.
Tien KJ, Tu ST, Chou CW, Yang CY, Hsiao JY, Shin SJ, Chen HC, Hsieh MC (2011) Apolipoprotein E polymorphism and the progression of diabetic nephropathy in type 2 diabetes. Am J Nephrol 33(3):231–238PubMedCrossRef
15.
Willson TM, Lambert MH, Kliewer SA (2001) Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem 70:341–367PubMedCrossRef
16.
Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, Lane CR, Schaffner SF, Bolk S, Brewer C, Tuomi T, Gaudet D, Hudson TJ, Daly M, Groop L, Lander ES (2000) The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26(1):76–80PubMedCrossRef
17.
Herrmann SM, Ringel J, Wang JG, Staessen JA, Brand E (2002) Peroxisome proliferator-activated receptor-gamma2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: the Berlin Diabetes Mellitus (BeDiaM) Study. Diabetes 51(8):2653–2657PubMedCrossRef
18.
Caramori ML, Canani LH, Costa LA, Gross JL (2003) The human peroxisome proliferator-activated receptor gamma2 (PPARgamma2) Pro12Ala polymorphism is associated with decreased risk of diabetic nephropathy in patients with type 2 diabetes. Diabetes 52(12):3010–3013PubMedCrossRef
19.
Liu L, Zheng T, Wang F, Wang N, Song Y, Li M, Li L, Jiang J, Zhao W (2010) Pro12Ala polymorphism in the PPARG gene contributes to the development of diabetic nephropathy in Chinese type 2 diabetic patients. Diabetes Care 33(1):144–149PubMedCentralPubMedCrossRef
20.
De Cosmo S, Prudente S, Lamacchia O, Lapice E, Morini E, Di Paola R, Copetti M, Ruggenenti P, Remuzzi G, Vaccaro O, Cignarelli M, Trischitta V (2011) PPARgamma2 P12A polymorphism and albuminuria in patients with type 2 diabetes: a meta-analysis of case-control studies. Nephrol Dial Transplant 26(12):4011–4016PubMedCrossRef
21.
Stefanski A, Majkowska L, Ciechanowicz A, Frankow M, Safranow K, Parczewski M, Pilarska K (2006) Lack of association between the Pro12Ala polymorphism in PPAR-gamma2 gene and body weight changes, insulin resistance and chronic diabetic complications in obese patients with type 2 diabetes. Arch Med Res 37(6):736–743PubMedCrossRef
22.
Erdogan M, Karadeniz M, Eroglu Z, Tezcanli B, Selvi N, Yilmaz C (2007) The relationship of the peroxisome proliferator-activated receptor-gamma 2 exon 2 and exon 6 gene polymorphism in Turkish type 2 diabetic patients with and without nephropathy. Diabetes Res Clin Pract 78(3):355–359PubMedCrossRef
23.
Bhaskar LV, Mahin S, Ginila RT, Soundararajan P (2013) Role of the ACE ID and PPARG P12A polymorphisms in genetic susceptibility of diabetic nephropathy in a south indian population. Nephrourol Mon 5(3):813–817PubMedCentralPubMedCrossRef
24.
Ma L, Mondal AK, Murea M, Sharma NK, Tonjes A, Langberg KA, Das SK, Franks PW, Kovacs P, Antinozzi PA, Stumvoll M, Parks JS, Elbein SC, Freedman BI (2011) The effect of ACACB cis-variants on gene expression and metabolic traits. PLoS ONE 6(8):e23860PubMedCentralPubMedCrossRef
25.
Maeda S, Kobayashi MA, Araki S, Babazono T, Freedman BI, Bostrom MA, Cooke JN, Toyoda M, Umezono T, Tarnow L, Hansen T, Gaede P, Jorsal A, Ng DP, Ikeda M, Yanagimoto T, Tsunoda T, Unoki H, Kawai K, Imanishi M, Suzuki D, Shin HD, Park KS, Kashiwagi A, Iwamoto Y, Kaku K, Kawamori R, Parving HH, Bowden DW, Pedersen O, Nakamura Y (2010) A single nucleotide polymorphism within the acetyl-coenzyme A carboxylase beta gene is associated with proteinuria in patients with type 2 diabetes. PLoS Genet 6(2):e1000842PubMedCentralPubMedCrossRef
26.
Tang SC, Leung VT, Chan LY, Wong SS, Chu DW, Leung JC, Ho YW, Lai KN, Ma L, Elbein SC, Bowden DW, Hicks PJ, Comeau ME, Langefeld CD, Freedman BI (2010) The acetyl-coenzyme A carboxylase beta (ACACB) gene is associated with nephropathy in Chinese patients with type 2 diabetes. Nephrol Dial Transplant 25(12):3931–3934PubMedCentralPubMedCrossRef
27.
Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603–605PubMedCrossRef
28.
29.
30.
Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088–1101PubMedCrossRef
31.
Araki S, Koya D, Makiishi T, Sugimoto T, Isono M, Kikkawa R, Kashiwagi A, Haneda M (2003) APOE polymorphism and the progression of diabetic nephropathy in Japanese subjects with type 2 diabetes: results of a prospective observational follow-up study. Diabetes Care 26(8):2416–2420PubMedCrossRef
32.
Reis KA, Ebinc FA, Koc E, Demirci H, Erten Y, Guz G, Derici UB, Bali M, Soylemezoglu O, Arinsoy T, Sindel S (2011) Association of the angiotensinogen M235T and APO E gene polymorphisms in Turkish type 2 diabetic patients with and without nephropathy. Ren Fail 33(5):469–474PubMedCrossRef
33.
Ilhan N, Kahraman N, Seckin D, Colak R (2007) Apo E gene polymorphism on development of diabetic nephropathy. Cell Biochem Funct 25(5):527–532PubMedCrossRef
34.
Hsieh MC, Lin SR, Yang YC, Chen HC, Lin JN, Shin SJ (2002) Higher frequency of apolipoprotein E2 allele in type 2 diabetic patients with nephropathy in Taiwan. J Nephrol 15(4):368–373PubMed
35.
Akarsu E, Pirim I, Capoglu I, Kaya H, Akcak G, Unuvar N (2001) A relation between the apolipoprotein E genotypes and microalbuminuria in type 2 diabetes mellitus. Turk J Med Sci 31:59–64
36.
Kimura H, Suzuki Y, Gejyo F, Karasawa R, Miyazaki R, Suzuki S, Arakawa M (1998) Apolipoprotein E4 reduces risk of diabetic nephropathy in patients with NIDDM. Am J Kidney Dis 31(4):666–673PubMedCrossRef
37.
Eto M, Horita K, Morikawa A, Nakata H, Okada M, Saito M, Nomura M, Abiko A, Iwashima Y, Ikoda A et al (1995) Increased frequency of apolipoprotein epsilon 2 allele in non-insulin dependent diabetic (NIDDM) patients with nephropathy. Clin Genet 48(6):288–292PubMedCrossRef
38.
Zhang H, Zhu S, Chen J, Tang Y, Hu H, Mohan V, Venkatesan R, Wang J, Chen H (2012) Peroxisome proliferator–activated receptor gamma polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: evidence from meta-analysis of 18 studies. Diabetes Care 35(6):1388–1393PubMedCentralPubMedCrossRef
39.
Lapice E, Pinelli M, Riccardi G, Vaccaro O (2010) Pro12Ala polymorphism in the PPARG gene contributes to the development of diabetic nephropathy in Chinese type 2 diabetic patients: comment on the study by Liu et al. Diabetes Care 33 (8):e114; author reply e115
40.
De Cosmo S, Motterlini N, Prudente S, Pellegrini F, Trevisan R, Bossi A, Remuzzi G, Trischitta V, Ruggenenti P (2009) Impact of the PPAR-gamma2 Pro12Ala polymorphism and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: evidence from BENEDICT. Diabetes 58(12):2920–2929PubMedCentralPubMedCrossRef
41.
Pollex RL, Mamakeesick M, Zinman B, Harris SB, Hegele RA, Hanley AJ (2007) Peroxisome proliferator-activated receptor gamma polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes. J Diabetes Complications 21(3):166–171PubMedCrossRef
42.
Mori H, Ikegami H, Kawaguchi Y, Seino S, Yokoi N, Takeda J, Inoue I, Seino Y, Yasuda K, Hanafusa T, Yamagata K, Awata T, Kadowaki T, Hara K, Yamada N, Gotoda T, Iwasaki N, Iwamoto Y, Sanke T, Nanjo K, Oka Y, Matsutani A, Maeda E, Kasuga M (2001) The Pro12 –>Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes 50(4):891–894PubMedCrossRef
43.
Horita K, Eto M, Makino I (1994) Apolipoprotein E2, renal failure and lipid abnormalities in non-insulin-dependent diabetes mellitus. Atherosclerosis 107(2):203–211PubMedCrossRef
44.
Maeda A, Gohda T, Funabiki K, Horikoshi S, Tomino Y (2004) Peroxisome proliferator-activated receptor gamma gene polymorphism is associated with serum triglyceride levels and body mass index in Japanese type 2 diabetic patients. J Clin Lab Anal 18(6):317–321PubMedCrossRef
45.
Buzello M, Tornig J, Faulhaber J, Ehmke H, Ritz E, Amann K (2003) The apolipoprotein e knockout mouse: a model documenting accelerated atherogenesis in uremia. J Am Soc Nephrol 14(2):311–316PubMedCrossRef
46.
Li Y, Tang K, Zhang Z, Zhang M, Zeng Z, He Z, He L, Wan C (2011) Genetic diversity of the apolipoprotein E gene and diabetic nephropathy: a meta-analysis. Mol Biol Rep 38(5):3243–3252PubMedCrossRef
47.
Mooyaart AL, Valk EJ, van Es LA, Bruijn JA, de Heer E, Freedman BI, Dekkers OM, Baelde HJ (2011) Genetic associations in diabetic nephropathy: a meta-analysis. Diabetologia 54(3):544–553PubMedCentralPubMedCrossRef
48.
Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J (1998) A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20(3):284–287PubMedCrossRef
49.
Jia Z, Sun Y, Yang G, Zhang A, Huang S, Heiney KM, Zhang Y (2014) New Insights into the PPAR Agonists for the treatment of diabetic nephropathy. PPAR Res 2014:818530PubMedCentralPubMed
50.
Wahba IM, Mak RH (2007) Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. Clin J Am Soc Nephrol 2(3):550–562PubMedCrossRef
51.
Jiang T, Wang Z, Proctor G, Moskowitz S, Liebman SE, Rogers T, Lucia MS, Li J, Levi M (2005) Diet-induced obesity in C57BL/6 J mice causes increased renal lipid accumulation and glomerulosclerosis via a sterol regulatory element-binding protein-1c-dependent pathway. J Biol Chem 280(37):32317–32325PubMedCrossRef
52.
Wang Z, Jiang T, Li J, Proctor G, McManaman JL, Lucia S, Chua S, Levi M (2005) Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb/db mice with type 2 diabetes. Diabetes 54(8):2328–2335PubMedCrossRef
Metadata
Title
The association between lipid metabolism gene polymorphisms and nephropathy in type 2 diabetes: a meta-analysis
Authors
Tingting Li
Yun Shi
Jieyun Yin
Qin Qin
Sheng Wei
Shaofa Nie
Li Liu
Publication date
01-01-2015
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 1/2015
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-014-0843-6

Other articles of this Issue 1/2015

International Urology and Nephrology 1/2015 Go to the issue

Nephrology - Original Paper

Predictors for and impact of high peritonitis rate in Taiwanese continuous ambulatory peritoneal dialysis patients

Nephrology - Original Paper

Timing of nephrology referral and initiation of dialysis as predictors for survival in hemodialysis patients: 5-year follow-up analysis

Nephrology – Original Paper

Low-dose cholecalciferol supplementation and dual vitamin D therapy in haemodialysis patients

Urology - Original Paper

Effectiveness of partial adrenalectomy for concomitant hypertension in patients with nonfunctional adrenal adenoma

Urology – Original Paper

Urinary TGF-1 has a supplementary value in predicting renal function recovery post unilateral ureteral obstruction

Urology - Original Paper

Assessment of testicular perfusion prior to sperm extraction predicts success rate and decreases the number of required biopsies in patients with non-obstructive azoospermia
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits